American Association for Cancer Research
00085472can171007-sup-181503_2_supp_4242931_4v4h4m.docx (109.92 kB)

Supplementary Figure Legend from Tethering IL2 to Its Receptor IL2Rβ Enhances Antitumor Activity and Expansion of Natural Killer NK92 Cells

Download (109.92 kB)
journal contribution
posted on 2023-03-31, 01:45 authored by Youssef Jounaidi, Joseph F. Cotten, Keith W. Miller, Stuart A. Forman

Supplementary Figure Legend including Supplementary Table 1: Primers used for Expression profiles of cytotoxicity effectors in NK92, NK92IL2 and NK92CIRB. Supplementary Tabel 2: Impact of direct contact with cancer cells on NK cells expression profiles of natural cytotoxicity and effectors. Supplementary Figure 1: Representation of the chimera CIRB. Supplementary Figure 2: Cell growth of NK92IL2 and NK92CIRB cell lines.






IL2 is an immunostimulatory cytokine for key immune cells including T cells and natural killer (NK) cells. Systemic IL2 supplementation could enhance NK-mediated immunity in a variety of diseases ranging from neoplasms to viral infection. However, its systemic use is restricted by its serious side effects and limited efficacy due to activation of T regulatory cells (Tregs). IL2 signaling is mediated through interactions with a multi-subunit receptor complex containing IL2Rα, IL2Rβ, and IL2Rγ. Adult natural killer (NK) cells express only IL2Rβ and IL2Rγ subunits and are therefore relatively insensitive to IL2. To overcome these limitations, we created a novel chimeric IL2-IL2Rβ fusion protein of IL2 and its receptor IL2Rβ joined via a peptide linker (CIRB). NK92 cells expressing CIRB (NK92CIRB) were highly activated and expanded indefinitely without exogenous IL2. When compared with an IL2-secreting NK92 cell line, NK92CIRB were more activated, cytotoxic, and resistant to growth inhibition. Direct contact with cancer cells enhanced the cytotoxic character of NK92CIRB cells, which displayed superior in vivo antitumor effects in mice. Overall, our results showed how tethering IL2 to its receptor IL2Rβ eliminates the need for IL2Rα and IL2Rβ, offering a new tool to selectively activate and empower immune therapy. Cancer Res; 77(21); 5938–51. ©2017 AACR.

Usage metrics

    Cancer Research



    Ref. manager